Pregled bibliografske jedinice broj: 833503
Patients complience correlates to pharmacogenomics of drugs used in the treatment of early stage breast cancer
Patients complience correlates to pharmacogenomics of drugs used in the treatment of early stage breast cancer // IUAES - World anthropologies and privatization of knwoledge: engaing anthropology in public
Dubrovnik, Hrvatska, 2016. str. xx-xx (poster, nije recenziran, sažetak, ostalo)
CROSBI ID: 833503 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Patients complience correlates to pharmacogenomics of drugs used in the treatment of early stage breast cancer
Autori
Bojanić, Kristina ; Kizivat, Tomislav ; Kuna, Lucija ; Wagner, Jasenka ; Smolić, Robert ; Bilić-Čurčić, Ines ; Kralik, Kristina ; Smolić, Martina, Tucak, Antun ; Včev, Aleksandar
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
IUAES - World anthropologies and privatization of knwoledge: engaing anthropology in public
/ - , 2016, Xx-xx
Skup
IUAES - World anthropologies and privatization of knwoledge: engaing anthropology in public
Mjesto i datum
Dubrovnik, Hrvatska, 04.05.2016. - 09.05.2016
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
pharmacogenetics ; breast cancer ; aromatase inhibitor ; adverse drug reactions ; osteoporosis ; hepatotoxicty
Sažetak
Anastrozole is a selective competitive aromatase inhibitor (AI) widely used as adjuvant treatment for early stage breast cancer. Highly efficient estrogen depletion by AI benefits breast cancer (BC) patients by extending recurrence-free survival. However, AIs put patients at high risk of osteoporosis due to the central role of estrogen in maintaining normal bone metabolism. Although awareness of osteoporosis by health care professionals has increased in recent years, it remains underdiagnosed and undertreated. Findings of this study should raise awarness of the importance of BMD screening among BC patients treated with anastrazole and to tailor treatment and prevention strategies for Al users as a high - risk population for bone morbidity. The intensity of adverse effects plays an essential part in maintaining patient complience to anastrazole therapy. Functional genetic polymorphisms of enzymes involved in anastrazole metabolism could be correlated to altered aromatase activity, disease prognosis and severity of aromatase inhibitor adverse effects, however large genotyping studies are obligatory.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Osijek
Profili:
Robert Smolić
(autor)
Ines Bilić-Ćurčić
(autor)
Lucija Kuna Roguljić
(autor)
Tomislav Kizivat
(autor)
Jasenka Wagner
(autor)
Kristina Bojanić
(autor)
Kristina Kralik
(autor)
Aleksandar Včev
(autor)
Martina Smolić
(autor)